ClinicalTrials.gg
CompletedNCT03068481Updated Apr 1, 2019

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

A Phase 1 interventional study of KDT-3594 and Placebo in Parkinson Disease, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-01.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Parkinson Disease with a site in Japan — 9 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Japan.

Enrollment
43rd of 60
36 · median 99
Started
2017
with 2 others
Phase 1
13 of 75
4 open now
Registered
42nd of 75
by date
Lead sponsor
4 of 75
Kissei Pharmaceutical Co., Ltd.

Among the 75 studies in Parkinson Disease with a site in Japan, this one is the 43rd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2017, is one of 13 in phase 1, and was the 42nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

9 of the 75 studies in Parkinson Disease with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Parkinson Disease with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study in healthy adult males is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594.

The purpose of this study in patients with Parkinson's disease is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The exploratory efficacy of KDT-3594 will also be investigated.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer part

    • Healthy Japanese males aged 20 to 35 years, inclusive
  • Patient part

    • Patients who are diagnosed with Parkinson's disease according to UK Parkinson's Disease society brain bank clinical diagnostic criteria
    • Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr Scale
    • Male patients with Parkinson's disease aged 20 to 74 years inclusive, female patients with Parkinson's disease aged 50 to 74 years inclusive

Exclusion criteria

Exclusion Criteria:

  • Healthy volunteer part

    • Subjects with any abnormal findings in physical examination vital signs, 12-lead , clinical laboratory tests, ophthalmic examinations and electroencephalography
  • Patient part

    • Patients who are suspected any parkinsonism except for idiopathic Parkinson's disease
  • Healthy volunteer part and patient part

    • Subjects who do not agree to avoid dangerous works such as driving, mechanical operation and high-place work until completion of the follow-up examination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Healthy volunteer part -Single dose

    Single oral dose of KDT-3594

    Drug: KDT-3594

  • Experimental
    Healthy volunteer part -Multiple dose

    Multiple oral doses of KDT-3594

    Drug: KDT-3594

  • Placebo comparator
    Healthy volunteer part -Placebo

    Multiple oral doses of Placebo

    Drug: Placebo

  • Experimental
    Patient part -Single dose

    Single oral dose of KDT-3594

    Drug: KDT-3594

  • Experimental
    Patient part -Multiple dose

    Multiple oral doses of KDT-3594

    Drug: KDT-3594

Interventions

  • Oral administration

  • DrugPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events

    Time frame: Up to 15 days after last administration

  2. Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: Cmax

    Time frame: Up to 336 hours after last administration

  3. Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: AUC

    Time frame: Up to 336 hours after last administration

Secondary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS) score (Only patient part)

    Time frame: Up to 336 hours after last administration

07

Study locations

1 site
  • Kyushu And Other Regions, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Aug 2018, 17 months.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 17 months is above that.

Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2017
First posted
Mar 1, 2017
StartActual
Feb 20, 2017
Primary completionActual
Aug 13, 2018
CompletionActual
Aug 13, 2018
Last update
Apr 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03068481
Responsible party
Sponsor
First posted
Mar 1, 2017
Start date
Feb 20, 2017
Primary completion
Aug 13, 2018
Completion
Aug 13, 2018
Last update
Apr 1, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KDT-3594

Start the discussion